So sticking with Lutetium PSMA 617, or actually if broadening that to PSMA targeted radionuclide therapy in general, one of the major questions is what about earlier disease states? The VISION trial was designed for those that had literally every single therapy that was known to benefit them prior to coming in.
So it’s nice to know that it works there, but what about in early lines of therapy? And in early lines of therapy, does it work better or the same or worse than some of the existing therapy? So that’s an unknown question, as well as combinations...
So sticking with Lutetium PSMA 617, or actually if broadening that to PSMA targeted radionuclide therapy in general, one of the major questions is what about earlier disease states? The VISION trial was designed for those that had literally every single therapy that was known to benefit them prior to coming in.
So it’s nice to know that it works there, but what about in early lines of therapy? And in early lines of therapy, does it work better or the same or worse than some of the existing therapy? So that’s an unknown question, as well as combinations.
The three drugs that are in phase three trials all use the beta emitter Lutetium 177. I’m very interested in looking at alphas, which are more potent, although a shorter range. So we’ll see if those will pan out, because it does look like they have activity, even those that had prior Lutetium PSMA treatment.